(Reuters) -Eli Lilly on Tuesday raised its full-year profit forecast, betting on surging demand for its weight-loss treatment Zepbound and type 2 diabetes drug Mounjaro. Shares of the company rose ...
Eli Lilly on Tuesday raised its full-year profit forecast, betting on surging demand for its weight-loss treatment Zepbound ...
Explosive demand and increased manufacturing capacity for Eli Lilly's weight-loss drug Zepbound drove the company to raise ...
Eli Lilly said its sees growth from key treatments such as Trulicity, Taltz and Verzenio driving 2021 revenues to around $28 billion. Eli Lilly said 2020 revenues should come in between $24.2 ...
(Reuters) -Eli Lilly raised its full-year profit and revenue forecast on Tuesday after demand for its weight-loss treatment ...
Analysts had expected sales of $2.08 billion. Eli Lilly raised its annual profit forecast by $1.30 per share to a range of $13.50 to $14 per share. The drugmaker also bumped its annual forecast by $2 ...
said CEO David Ricks. Eli Lilly & Co. (LLY) posted stronger-than-expected fourth quarter earnings Thursday, while lifting its full-year profit forecast, as sales of its blockbuster diabetes ...
Eli Lilly raised both ends of its 2024 revenue forecast by $2 billion and now expects $42.4 billion to $43.6 billion for the year. The drugmaker also raised its annual profit forecast by $1.30 per ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Soaring sales of Eli Lilly’s hugely popular diabetes and weight loss drugs Mounjaro and Zepbound prompted ...
Soaring sales of Eli Lilly’s hugely popular diabetes and weight-loss drugs Mounjaro and Zepbound prompted the US pharmaceutical group to lift its guidance for the year and pushed its share price ...
757.70$ -2.30(-0.30%) 現在値(5/13 16:00) / 前日比 医薬品の開発・製造を手掛け、約105カ国で販売する。 米インディアナポリスに主要研究開発施設 ...